151 related articles for article (PubMed ID: 20620393)
1. Cadherin switching and bladder cancer.
Bryan RT; Tselepis C
J Urol; 2010 Aug; 184(2):423-31. PubMed ID: 20620393
[TBL] [Abstract][Full Text] [Related]
2. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.
Bryan RT; Atherfold PA; Yeo Y; Jones LJ; Harrison RF; Wallace DM; Jankowski JA
J Pathol; 2008 Jun; 215(2):184-94. PubMed ID: 18393367
[TBL] [Abstract][Full Text] [Related]
3. Expression of classic cadherins type I in urothelial neoplastic progression.
Rieger-Christ KM; Cain JW; Braasch JW; Dugan JM; Silverman ML; Bouyounes B; Libertino JA; Summerhayes IC
Hum Pathol; 2001 Jan; 32(1):18-23. PubMed ID: 11172290
[TBL] [Abstract][Full Text] [Related]
4. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
[TBL] [Abstract][Full Text] [Related]
5. Expression of beta1-integrins and N-cadherin in bladder cancer and melanoma cell lines.
Laidler P; Gil D; Pituch-Noworolska A; Ciołczyk D; Ksiazek D; Przybyło M; Lityńska A
Acta Biochim Pol; 2000; 47(4):1159-70. PubMed ID: 11996105
[TBL] [Abstract][Full Text] [Related]
6. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.
Clairotte A; Lascombe I; Fauconnet S; Mauny F; Félix S; Algros MP; Bittard H; Kantelip B
Am J Clin Pathol; 2006 Jan; 125(1):119-26. PubMed ID: 16483000
[TBL] [Abstract][Full Text] [Related]
7. [Study on E-cadherin expression in relation to invasion and metastasis in urothelial cancer patients].
Kawakita M; Moroi S; Kyotani K; Kakehi Y; Yoshida O
Hinyokika Kiyo; 1994 Dec; 40(12):1077-80. PubMed ID: 7863859
[TBL] [Abstract][Full Text] [Related]
8. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
[TBL] [Abstract][Full Text] [Related]
9. Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer.
Syrigos KN; Harrington K; Waxman J; Krausz T; Pignatelli M
J Urol; 1998 Nov; 160(5):1889-93. PubMed ID: 9783980
[TBL] [Abstract][Full Text] [Related]
10. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
12. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
13. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
[TBL] [Abstract][Full Text] [Related]
14. Dominant role of E-cadherin in the progression of bladder cancer.
Imao T; Koshida K; Endo Y; Uchibayashi T; Sasaki T; Namiki M
J Urol; 1999 Feb; 161(2):692-8. PubMed ID: 9915485
[TBL] [Abstract][Full Text] [Related]
15. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas.
De Medina SG; Popov Z; Chopin DK; Southgate J; Tucker GC; Delouvée A; Thiery JP; Radvanyi F
Oncogene; 1999 Oct; 18(41):5722-6. PubMed ID: 10523852
[TBL] [Abstract][Full Text] [Related]
16. Cadherin switching in human prostate cancer progression.
Tomita K; van Bokhoven A; van Leenders GJ; Ruijter ET; Jansen CF; Bussemakers MJ; Schalken JA
Cancer Res; 2000 Jul; 60(13):3650-4. PubMed ID: 10910081
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.
Pyo SW; Hashimoto M; Kim YS; Kim CH; Lee SH; Johnson KR; Wheelock MJ; Park JU
J Craniomaxillofac Surg; 2007 Jan; 35(1):1-9. PubMed ID: 17296306
[TBL] [Abstract][Full Text] [Related]
18. P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.
Mandeville JA; Silva Neto B; Vanni AJ; Smith GL; Rieger-Christ KM; Zeheb R; Loda M; Libertino JA; Summerhayes IC
BJU Int; 2008 Dec; 102(11):1707-14. PubMed ID: 18990147
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]